Farallon Capital Management’s Travere Therapeutics TVTX Stock Holding History

Farallon Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$357K	Hold	12,000	–	–	﹤0.01%	112
2025 Q4	$459K	Hold	12,000	–	–	﹤0.01%	96
2025 Q3	$287K	Hold	12,000	–	–	﹤0.01%	105
2025 Q2	$178K	Buy	+12,000	New	+$199K	﹤0.01%	124
2024 Q1	–	Sell	-1,094,000	Closed	-$9.84M	–	187
2023 Q4	$9.84M	Buy	1,094,000 +822,483	+303%	+$5.99M	0.05%	81
2023 Q3	$2.43M	Buy	+271,517	New	+$3.83M	0.01%	106

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Farallon Capital Management's TVTX Position: Q1 2026 in Review

Farallon Capital Management held its Travere Therapeutics (TVTX) position steady in Q1 2026 at 12,000 shares worth $357K. The position accounts for ﹤0.01% of the portfolio, ranked #112.

Farallon Capital Management first reported a position in TVTX in Q3 2023 and has held it in 6 quarters since. The position peaked at $9.84M in Q4 2023. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

Farallon Capital Management held 12,000 shares of Travere Therapeutics worth $357K as of Q1 2026.
Farallon Capital Management left its Travere Therapeutics share count unchanged in Q1 2026.
Travere Therapeutics made up ﹤0.01% of Farallon Capital Management's portfolio in Q1 2026, its #112 holding.
Farallon Capital Management first reported a position in Travere Therapeutics in Q3 2023 and has held it in 6 quarters since.
Farallon Capital Management's Travere Therapeutics position peaked at $9.84M in Q4 2023.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.